Drug Channels News Roundup, September 2025: Mark Cuban Wins (Again), Biosimilar Pricing Double Standards, Part D Collapse, Fresh 340B Facts, and The Pitt

Autumn is here! Curl up with your Labubu’s favorite pumpkin-spiced blog and savor these stories harvested from the great Drug Channels patch:

• Mark Cuban’s company trims third-party fat but insured patients sometimes pay more

• Express Scripts boots Stelara, but clings to its biosimilar pricing double standard

• Thanks, IRA! The Part D market keeps unravelling

• Fresh insights from two government reports on the 340B Drug Pricing Program

Plus: If you loved The Pitt, you'll love the sequel!

P.S. Join my 65,000+ LinkedIn followers for curated links to neat stuff, along with sharp and thoughtful commentary from the DCI community.

Drug Channels Leadership Forum 2026

Drug Channels Institute is proud to host the 2026 Drug Channels Leadership Forum, which will take place from March 16–18, 2026, in Miami. Check out the agenda and request your invitation to this invite-only gathering of senior leaders from across the drug channel ecosystem. You must request an invitation to be considered for attendance. We will begin sending invitations in mid-October.

Read more »

Source: Post feed